Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine + capecitabine with or without GV1001 telomerase vaccine in advanced pancreatic cancer
ISRCTN43482138Phase 3Completed
- Sponsor
- University of Liverpool
- Start
- Apr 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, capecitabine and tertomotide in pancreatic adenocarcinoma (PDAC) (3 arms), sponsored by University of Liverpool. Primary endpoint: Overall survival. Started Apr 2006; status: completed.
02
Drugs
gemcitabinecapecitabinetertomotide
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ISRCTN43482138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN43482138.